Serglycin, a new prognostic biomarker for cancer in dogs

Last changed: 17 February 2022
A dog is examined by a veterinarian, photo.

Cancer in various forms affects dogs as well as humans. More than half of all dogs over the age of 10 are diagnosed with cancer. Health information from more than 350,000 Swedish dogs, compiled from insurance statistics, shows that cancer is the most common cause of death in dogs. In this project, the protein serglycin is evaluated as a potential prognostic biomarker for cancer in dogs.

Go to the Swedish version of this page to read more and to find contact details for the researchers involved.






The one-year project was launched in 2018 and was financed by SLU Future One Health (previously SLU Future Animals, Nature and Health).

SLU Future One Health supports interdisciplinary research that is part of the One Health concept – optimal health and welfare for both humans and animals in sustainable ecosystems.

Read more about SLU Future One Health, ongoing research projects and forthcoming funding opportunities.